YPS345

YPS345 is an investigational, orally bioavailable small molecule inhibitor developed by Tianfang Pharmaceutical Co., Ltd. It specifically targets the Transforming Growth Factor-beta (TGF-β) signaling pathway, which is a critical mediator of inflammation and fibrosis in various pathological conditions. The drug is primarily being developed for the prevention and treatment of radiation-induced lung injury, specifically radiation pneumonitis, in patients undergoing thoracic radiotherapy for lung cancers. By inhibiting the TGF-β receptor, YPS345 aims to suppress the fibrotic cascade and inflammatory response triggered by ionizing radiation, thereby reducing pulmonary toxicity. Additionally, YPS345 is being evaluated for its potential anti-tumor effects in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), as TGF-β signaling is also implicated in tumor immune evasion and metastasis.